Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Phase 3 Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment of Patients With Pancreatic Adenocarcinoma

Trial Profile

A Randomized, Phase 3 Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment of Patients With Pancreatic Adenocarcinoma

Recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Nov 2018

At a glance

  • Drugs ERY-ASP (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan; Paclitaxel
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms TRYbeCA-1
  • Sponsors ERYtech Pharma
  • Most Recent Events

    • 15 Nov 2018 According to an ERYtech Pharma media release, the company has a red blood cell supply and research partnership with New York Blood Center (NYBC) for this and other trial (see profile 293090). The company is planning to begin enrollment in the United States early in 2019.
    • 12 Nov 2018 According to an ERYtech Pharma media release, an interim analysis is foreseen when approximately two-thirds of events have occurred.
    • 20 Sep 2018 According to an ERYtech Pharma media release, Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top